{
    "Case ID": "089505",
    "Crime_Name": [
        "Patent Infringement Dispute"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent Infringement Dispute"
    ],
    "Legal_Issue": [
        "Validity of the '330 patent, including claim scope and sound prediction"
    ],
    "Governing_Law": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Procedural_Stage": [
        "Prohibition application under NOC Regulations"
    ],
    "Evidence_Assessment": [
        "Federal Court of Appeal previously upheld the patent; Novopharm's new evidence on stereoisomer invention not conclusive"
    ],
    "Decision_Outcome": [
        "Applications for prohibition allowed"
    ],
    "Burden_of_Proof": [
        "On Novopharm to demonstrate invalidity of the patent"
    ],
    "Credibility_Factor": [
        "Novopharm's evidence deemed not strong enough to overturn prior findings"
    ],
    "Legal_Rule": [
        "A patent is invalid if claims exceed the actual invention or lack utility due to unsound prediction"
    ],
    "Standard_of_Review": [
        "Reasonableness or correctness in administrative and appellate review context"
    ],
    "Procedural_Issue": [
        "Proceedings initiated by Pfizer after Notices of Allegation from Novopharm"
    ],
    "Grounds_for_Claim": [
        "Invalidity based on overbroad claims and lack of sound prediction"
    ],
    "Outcome_on_Merits": [
        "Pfizer succeeded; patent upheld as valid"
    ],
    "Decision_Maker": [
        "Federal Court of Appeal"
    ],
    "Judicial_Review_Outcome": [
        "Prohibition applications allowed"
    ],
    "Review_Standard": [
        "Assessment of whether patent claims are supported by invention and utility"
    ],
    "Procedural_Fairness_Assessment": [
        "Procedures followed under NOC Regulations were observed"
    ],
    "Key_Evidence_Considered": [
        "Prior data supporting utility prediction; evidence on stereoisomer development"
    ],
    "Legal_Framework": [
        "NOC Regulations framework for patent disputes in pharmaceuticals"
    ],
    "Applicant_Challenge": [
        "Novopharm challenged validity of '330 patent to market generic quinapril"
    ],
    "Court_Result": [
        "Pfizer prohibited Novopharm from regulatory approval until patent expiry"
    ],
    "Legal_Rule_Source": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Standard_of_Proof": [
        "Balance of probabilities"
    ],
    "Defendant_Response": [
        "Novopharm argued only S,S,S stereoisomer was invented and prediction unsound"
    ],
    "Evidence_Type": [
        "Scientific data, prior art, expert testimony"
    ],
    "Remedy_Requested": [
        "Regulatory approval for generic drug"
    ],
    "Outcome": [
        "Prohibition granted; generic entry blocked until patent expiration"
    ],
    "Decision_Authority": [
        "Federal Court of Appeal"
    ],
    "Remedy_Sought": [
        "Prevention of generic market entry via NOC prohibition"
    ],
    "Resolution_Mechanism": [
        "Judicial determination under NOC Regulations"
    ],
    "Legal_Provision": [
        "Sections of the Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Authority": [
        "Canadian Federal Courts"
    ],
    "Claimant_Status": [
        "Pfizer as innovator holding '330 patent"
    ],
    "Legal_Provision_Cited": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Invalidity due to overbroad claims and insufficient utility prediction"
    ],
    "Applicable_Process": [
        "Notice of Allegation and prohibition application process"
    ],
    "Outcome_of_Review": [
        "Patent upheld, prohibition maintained"
    ],
    "Pending_Relief_or_Application": [
        "Application for prohibition under NOC Regulations"
    ],
    "Jurisdiction": [
        "Canada, Federal Court"
    ],
    "Governing_Rule": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ]
}